As they demonstrated in vivo efficacy in the EAE model, and due to their S1P1-selective nature, we speculate that they will exhibit fewer adverse effects and have an advantage over fingolimod and siponimod, not only in MS but also in other autoimmune diseases. This evidence concerns the gene S1PR1 and myeloid sarcoma.